➤ Enrollment complete in first-in-human trial evaluating treatment for patients with Usher syndrome ➤ First patients randomized in drug-eluting IOL trial ➤ Preliminary data from Phase 2 gene modifier study for geographic atrophy ➤ ASCRS news and events
When it comes to refractive procedures, there are many options available. Several physicians discussed what they’re using and the options available, notably market penetration of the Implantable Collamer Lens (ICL, STAAR Surgical) and SMILE in different areas and how this has changed over the years.
➤ FDA approves new viscoelastic system ➤ Expanded label approved for geographic atrophy treatment ➤ Biologics application accepted for aflibercept biosimilar ➤ Update on gene therapy program ➤ ASCRS news and events
➤ Topline Phase 3 pivotal study for BRIMOCHOL for treatment of presbyopia ➤ Positive Phase 2b/3 results for oral treatment of thyroid eye disease ➤ Clinical plan for first-in-human trial for investigational dry AMD therapy ➤ Update on registrational program therapy targeting various retinal diseases ➤ Collaboration to develop RNAi program targeting geographic atrophy ➤ ASCRS news and events
➤ FDA approves drop for mydriasis reversal ➤ Inventors of OCT honored with ‘American Nobel Prize’ ➤ Preservative-free latanoprost begins U.S. launch ➤ Enrollment complete in myopia treatment trial ➤ ASCRS news and events
➤ FDA approves treatment for subfoveal choroidal neovascularization due to AMD ➤ IND for inherited RPE clinical trial receives FDA clearance ➤ Phase 3 clinical trial to evaluate cooling device for anesthesia prior to injections ➤ Study calls ‘long-believed theory about diabetic cataracts into question’ ➤ ASCRS news and events